Three antidepressants outperform Prozac for long-term depression, largest study finds
A network meta-analysis of 115 trials and 30,000 patients finds escitalopram, agomelatine, and duloxetine significantly more likely than fluoxetine to keep patients well over six months or more.
For decades, fluoxetine — sold as Prozac — has been the reference point for antidepressant treatment. A new study — the largest ever to focus specifically on long-term antidepressant use — has determined that three other drugs, escitalopram (Lexapro), agomelatine (Valdoxan), and duloxetine (Cymbalta), are significantly more likely to keep patients well over six months or more. The findings, published November 10 in The Lancet Psychiatry, come from an international team led by Radboud University Medical Center and could reshape how clinicians choose a first antidepressant.
The research drew on 115 randomized controlled trials encompassing more than 30,000 participants, comparing 20 antidepressants against fluoxetine as a common reference. Where most prior drug comparisons gauge whether a medication lifts mood after six to eight weeks, this analysis set a higher bar, defining success as a sustained response — remaining above the treatment-response threshold at six months or longer — and used all-cause discontinuation as a secondary measure.
Against fluoxetine as the baseline, the results were clear. Patients on escitalopram had 62% higher odds of maintaining their response (odds ratio 1.62, 95% CI 1.21–2.18). Agomelatine showed 57% higher odds (OR 1.57, 95% CI 1.08–2.26). Duloxetine showed 40% higher odds (OR 1.40, 95% CI 1.06–1.85). Because all three confidence intervals exclude 1.0, each result clears the bar for statistical significance. Tech Times also noted a secondary finding: escitalopram and duloxetine both had lower rates of all-cause discontinuation than fluoxetine, which is clinically relevant given that stopping an antidepressant is itself associated with relapse risk.
The main question is, if someone comes into the consulting room with depression for the first time, which antidepressant gives the greatest chance that the person both recovers and does not relapse?— Paul van Haaren, first author, Radboud University Medical Center
To put the escitalopram finding in concrete terms: co-researcher Eric Ruhé explained that if eight people are treated with antidepressants, one additional person improves because of escitalopram compared with fluoxetine. According to Tech Times, translating that into population terms, where 100 fluoxetine patients maintained their response at six months, an estimated 162 patients on escitalopram would have achieved the same outcome under otherwise comparable conditions.
Of these SSRIs, escitalopram now appears to be the most effective, also for long-term use. This study may have implications for future treatment guidelines.— Eric Ruhé, Professor of Difficult to Treat Depression, Radboud University Medical Center
At the other end of the spectrum, the study identified two drugs — bupropion (Wellbutrin) and reboxetine — that showed lower odds of sustained response than fluoxetine, a result that, according to Tech Times, may give pause to clinicians who currently prescribe bupropion for long-term maintenance.
The scale of the problem the study addresses is significant. According to EurekAlert, depression affects nearly six percent of people globally. Approximately 1.2 million people in the Netherlands take antidepressants; of those, roughly half a million have remained on the same medication for more than two years, and about 300,000 start treatment each year. In the United States, roughly 21 million Americans are diagnosed with major depressive disorder each year, according to Tech Times.
The second-ranked drug, agomelatine, comes with a critical caveat for American patients: the US Food and Drug Administration has not approved it, and it cannot be obtained in the United States. The drug has been sold in the European Union under the brand name Valdoxan since 2009. Its mechanism is also distinct from the SSRIs and SNRIs that dominate prescribing — rather than blocking serotonin reuptake, agomelatine acts on melatonin receptors while simultaneously blocking serotonin 5-HT2C receptors, an approach thought to resynchronize disrupted circadian rhythms, according to Tech Times.
The reason agomelatine never reached the US market is tied to a liver risk. European regulators have found that the drug produces clinically significant elevations in liver enzymes in roughly 1 to 2.5% of patients, with the risk rising at higher doses. Six cases of hepatic failure worldwide had been linked to agomelatine use as of 2012 — some fatal, some requiring liver transplantation — and most involved patients who already carried liver risk factors such as obesity, alcohol use, or diabetes. Patients in Europe starting the drug must undergo liver function testing before treatment begins and at several points afterward. Anyone with existing hepatic impairment is barred from taking it, according to Tech Times.
Agomelatine works well, but one of its side effects is the risk of liver failure.— Eric Ruhé, Professor of Difficult to Treat Depression, Radboud University Medical Center
Psychiatrist Perry Anthony Maliuanag, who was not involved in the study, told Medical News Today that each of the three top-performing drugs carries its own profile of considerations. Escitalopram has one of the lowest drug-drug interaction rates, making it a strong option for patients with multiple medical conditions on multiple medications, but should be used with caution in patients at risk of QT prolongation, a condition affecting the heart's electrical activity. Duloxetine, which acts on both serotonin and norepinephrine and can also help patients with chronic pain, is best avoided in those with severely impaired kidney function. Agomelatine's circadian mechanism makes it theoretically well-suited to patients whose depression involves disrupted sleep rhythms, but its liver enzyme effects remain the main obstacle to wider use.
Although this study shows that there are some that may seem more effective than others, antidepressants as a whole are effective but may differ in response for the individual patient. The antidepressant choice should be discussed with their clinician with the intention of looking [at] which may be the right fit based on their presenting symptoms, medical co-morbidities, prior or current substance use or taking other prescription medications, and personal goals.— Perry Anthony Maliuanag, MD, FAPA, psychiatrist, Menlo Park Psychiatry & Sleep Medicine
The researchers and outside experts are consistent on one point: the findings apply to people starting medication, not to patients already doing well on a current drug. Fluoxetine remains effective; the study shows that some alternatives carry a higher probability of sustained response, not that Prozac fails. Personal factors — tolerance of sexual side effects, risk of weight gain, family history of response to a particular drug — remain part of the clinical conversation.
As a prescriber, you consider the balance between a medication's benefits and side effects. That balance differs from person to person. Therefore, the choice of medication may vary for each individual patient. Nevertheless, our study can help inform the decisions that prescribers and patients make together: if you start an antidepressant, choose one that not only helps you to get well, but also keeps you well.— Eric Ruhé, Professor of Difficult to Treat Depression, Radboud University Medical Center
The study's findings partially conflict with current Dutch treatment guidelines, which recommend citalopram, escitalopram, sertraline, and fluoxetine as preferred choices — a list that includes escitalopram but also retains fluoxetine as a first-line option, according to NL Times. The researchers say the results should inform future guideline updates internationally.
One significant methodological caveat: the study's authors disclosed that more than half of the 35 head-to-head continuation trials used in the primary analysis were flagged for bias risk, according to Tech Times. The network meta-analysis technique used — which allows comparisons between drugs that were never directly tested against each other by threading together direct and indirect comparisons — is a well-established but inherently indirect method. These limitations do not invalidate the findings but mean clinical decisions should weigh the evidence carefully rather than treat the odds ratios as definitive.
Why it matters — For the millions of people who take antidepressants long-term, this is the first large-scale evidence that the choice of drug — not just whether to take one — meaningfully affects the odds of staying well, and it names specific alternatives that outperform the most familiar option.
⚠ Not yet confirmed
- More than half of the 35 head-to-head continuation trials used in the primary analysis were flagged for bias risk
Sources differ on Odds ratio ranking order for agomelatine vs. duloxetine: Agomelatine OR 1.57 (second), duloxetine OR 1.40 (third) (techtimes.com) vs Agomelatine 57% higher odds, duloxetine 40% higher odds — same ranking but figures attributed differently in summary (medicalnewstoday.com)
Reported by thelancet.com, cleveland.com, nltimes.nl, techtimes.com, medicalnewstoday.com, eurekalert.org